What did Exact Sciences shareholders receive in the merger?

Each share of Exact Sciences common stock outstanding immediately before the effective time (other than certain excluded shares) was converted into the right to receive $105.00 in cash, without interest and less any applicable withholding taxes.

What products does Abbott acquire with Exact Sciences?

The acquisition brings Cologuard, a noninvasive colorectal cancer screening test; Oncotype DX, which guides treatment for early-stage breast cancer; Oncodetect, a tumor-informed molecular residual disease test; and Cancerguard, a multi-cancer early detection blood test. Abbott also gains a next-generation screening and diagnostics pipeline.

Why is Abbott making this acquisition?

Abbott says the deal establishes leadership in the fast-growing U.S. cancer screening and precision oncology diagnostics markets, which it values at about $60 billion, and advances its push toward more preventative, predictive, and personalized diagnostics. Management also says it adds a new growth vertical to Abbott's high-single-digit growth expectations.

Does this 8-K disclose the financial impact on Abbott?

No. The filing is a completion notice. It does not provide the total transaction value beyond the per-share price, financing details, purchase price allocation, pro forma results, or updated guidance. Those details would typically appear in Abbott's subsequent periodic reports or earnings communications.

When did Exact Sciences stop trading, and what are the main risks?

Exact Sciences' last day of trading on the Nasdaq was March 20, 2026. The press release flags risks including Abbott's ability to integrate Exact Sciences' operations, implement its business plans, and realize the anticipated synergies within the expected timeframe.

ABT 8-K SEC Disclosure — Mar 23, 2026

01—Abstract

Summary

Summary of the 8-K filed March 23, 2026. Cited figures are marked; the original filing is the authoritative source.

On March 23, 2026, Abbott Laboratories (NYSE: ABT) completed its acquisition of Exact Sciences Corporation under the Agreement and Plan of Merger dated November 19, 2025.

Merger Sub merged into Exact Sciences, which survives as a wholly owned Abbott subsidiary. Each Exact Sciences share was converted into the right to receive $105.00^a in cash, without interest and less applicable withholding taxes. Exact Sciences' last day of trading on Nasdaq was March 20, 2026.

Strategically, Abbott is adding a high-growth cancer screening and precision oncology franchise to its diagnostics business. Management cites a $60 billion^b U.S. cancer screening and precision oncology diagnostics market and says the deal adds a new growth vertical to Abbott's existing high-single-digit growth expectations. The acquired portfolio includes Cologuard (noninvasive colorectal cancer screening), Oncotype DX (breast cancer treatment guidance), Oncodetect (MRD testing), and Cancerguard (a multi-cancer early detection blood test), along with a next-generation pipeline.

The 8-K is primarily a completion notice and does not disclose purchase price accounting, financing terms, pro forma financials, or updated guidance. Investors should look to Abbott's upcoming filings for the financial impact, integration costs, and synergy targets. The press release's forward-looking statements flag integration execution and synergy realization risks.

02—Key points

Key Highlights

Abbott completed its acquisition of Exact Sciences on March 23, 2026, with Exact Sciences becoming a wholly owned subsidiary.
Exact Sciences shareholders receive $105.00 per share in cash, without interest and less applicable withholding taxes.
The deal adds Cologuard, Oncotype DX, Oncodetect, and Cancerguard, giving Abbott a cancer screening and precision oncology franchise.
Management targets the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
The transaction adds a new growth vertical to Abbott's high-single-digit growth expectations, per the press release.
The 8-K does not disclose deal value, financing, purchase accounting, or pro forma financial impact.
Key risks flagged include integration execution and the ability to realize expected synergies within the anticipated timeframe.

03—Questions

Frequently Asked Questions

What did Exact Sciences shareholders receive in the merger?
Each share of Exact Sciences common stock outstanding immediately before the effective time (other than certain excluded shares) was converted into the right to receive $105.00 in cash, without interest and less any applicable withholding taxes.
What products does Abbott acquire with Exact Sciences?
The acquisition brings Cologuard, a noninvasive colorectal cancer screening test; Oncotype DX, which guides treatment for early-stage breast cancer; Oncodetect, a tumor-informed molecular residual disease test; and Cancerguard, a multi-cancer early detection blood test. Abbott also gains a next-generation screening and diagnostics pipeline.
Why is Abbott making this acquisition?
Abbott says the deal establishes leadership in the fast-growing U.S. cancer screening and precision oncology diagnostics markets, which it values at about $60 billion, and advances its push toward more preventative, predictive, and personalized diagnostics. Management also says it adds a new growth vertical to Abbott's high-single-digit growth expectations.
Does this 8-K disclose the financial impact on Abbott?
No. The filing is a completion notice. It does not provide the total transaction value beyond the per-share price, financing details, purchase price allocation, pro forma results, or updated guidance. Those details would typically appear in Abbott's subsequent periodic reports or earnings communications.
When did Exact Sciences stop trading, and what are the main risks?
Exact Sciences' last day of trading on the Nasdaq was March 20, 2026. The press release flags risks including Abbott's ability to integrate Exact Sciences' operations, implement its business plans, and realize the anticipated synergies within the expected timeframe.

04—Continue

← View all 8-K filings